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Abstract
p-Cresol is a by-product of the metabolism of aromatic aminoacid operated by resident intestinal bacteria. In patients with
chronic kidney disease, the accumulation of p-cresol and of its metabolite p-cresyl-sulphate causes endothelial dysfunction
and ultimately increases the cardiovascular risk of these patients. Therapeutic strategies to reduce plasma p-cresol levels are
highly demanded but not available yet. Because it has been reported that the phosphate binder sevelamer sequesters p-
cresol in vitro we hypothesized that it could do so also in peritoneal dialysis patients. To explore this hypothesis we
measured total cresol plasma concentrations in 57 patients with end-stage renal disease on peritoneal dialysis, 29 receiving
sevelamer for the treatment of hyperphosphatemia and 28 patients not assuming this drug. Among the patients not
assuming sevelamer, 16 were treated with lanthanum whereas the remaining 12 received no drug because they were not
hyperphosphatemic. Patients receiving sevelamer had plasma p-cresol and serum high sensitivity C-reactive protein
concentrations significantly lower than those receiving lanthanum or no drug. Conversely, no difference was observed
among the different groups either in residual glomerular filtration rate, total weekly dialysis dose, total clearance, urine
volume, protein catabolic rate, serum albumin or serum phosphate levels. Multiple linear regression analysis showed that
none of these variables predicted plasma p-cresol concentrations that, instead, negatively correlated with the use of
sevelamer. These results suggest that sevelamer could be an effective strategy to lower p-cresol circulating levels in
peritoneal dialysis patients in which it could also favorably affect cardiovascular risk because of its anti-inflammatory effect.
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Introduction
Uremic toxins are a heterogeneous group of compounds that
accumulate in the plasma of patients with chronic kidney disease
(CKD). More than 90 different uremic toxins have been identified
up to day; based on their molecular weight and their affinity for
plasma proteins, they can be classified in three different groups:
small water soluble molecules not significantly bound to plasma
proteins, small molecules significantly bound to plasma proteins
and middle/large proteins [1]. The great interest that has been
accruing on uremic toxins over the years derives from experi-
mental evidence suggesting that some of them may have a
causative role in the development of long-term complications of
CKD and, in particular, of cardiovascular disorders [2], which are
major cause of death in this disease [3]. Recent evidence points to
p-cresol as one of the uremic toxins more directly implicated in the
pathogenesis of CKD complications. This aromatic compound is
generated in the gut by the degradation of tyrosine and
phenylalanine operated by resident intestinal flora [4–5]. After
absorption, p-cresol is converted into its conjugates p-cresylglu-
curonide and p-cresylsulfate. The latter, which represents more
than 95% of circulating p-cresol, is responsible for the majority of
p-cresol toxic effects [6]. The plasma concentrations of p-cresol
and p-cresylsufate, which belong to the subgroup of small
molecules significantly bound to plasma proteins, are strongly
related to cardiovascular risk in CKD [6–9] and are predictive of
mortality in these patients [10]. This is consistent with a number of
studies in vitro that clearly showed that p-cresol and its derivative p-
cresylsulphate are toxic for endothelial cells and can cause
endothelial dysfunction [11–13]. Intense efforts are currently
directed to identify the best therapeutic strategy to lower uremic
toxins in CKD patients because it has been shown that this can
lead to a significant improvement in their survival [14].
Unfortunately, dialysis seems to be effective only in removing
small water soluble uremic toxins whereas those significantly
bound to plasma proteins are significantly retained despite the
dialysis treatment [15]. Specifically, p-cresol and its sulphate
derivative are extremely difficult to dialyze [16]. An interesting
alternative approach to lower the plasma concentrations of p-
cresol is directed to lowering its intestinal absorption [17]. The
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rationale behind this strategy is that all circulating p-cresol is
derived from that produced by bacteria in the gut because this
compound cannot be generated by the metabolism of aromatic
aminoacids by human cells [17]. Studies in vitro showed that the
non-calcium non-aluminum containing phosphate binder sevela-
mer hydrochloride (Sev), which is largely used to treat hyperphos-
phatemia in end stage renal disease (ESRD) [18–19], also binds p-
cresol [20]. This evidence suggested that this orally administered
phosphate binder could lower p-cresol concentrations in human
patients with CKD by preventing its intestinal absorption.
Contrarily to these expectations, Brandeburg et al. (2010) [21]
reported that p-cresol plasma concentrations were significantly
higher at the end of an 8 week treatment with Sev than before it
was started and, importantly, that they returned at their basal
levels when the treatment with this drug was stopped. However,
this remains the only study that explored the effects of Sev on p-
cresol in hemodialysis patients. In addition, the impact of the
treatment with this drug on p-cresol levels in peritoneal dialysis
(PD) patients has never been investigated. Considering this lack of
information, in the present cross-sectional observational study,
performed on a cohort of 57 patients with ESRD treated with PD,
we compared p-cresol plasma concentrations in patients assuming
Sev for the treatment of ESRD-induced hyperphosphatemia and in
those not treated with this drug.
Patients and Methods
Study Design
The present study has a monocentric cross-sectional observa-
tional design. All the patients undergoing PD at the Division of
Nephrology of the Federico II University of Naples were
considered for recruitment. The inclusion criteria were: age .18
years, dialysis age .6 months, a good compliance to medical and
dialysis treatment, and, for the patients assuming Sev or
lanthanum, a stable therapeutic regimen with either of these
phosphate binders from at least six months. Exclusion criteria were:
malnutrition, malignant neoplasms, and current history of
gastrointestinal and/or endocrine diseases.
All subjects gave their written informed consent to participate
the study that was performed in accordance with the indications of
the WMA Declaration of Helsinki. As required by Italian
regulations governing observational studies (AIFA document of
20/3/2008), a formal notification of the study was sent to the
Ethics Committee of the Federico II University of Naples.
Detailed demographic and clinical history data were already
available for each patient at the time of recruitment as their
collection is part of the standard protocol applied for all the
patients followed at our institution. Blood samples for the
determination of blood chemistry and of p-cresol were collected
in the morning from all patients recruited for the study. For data
analysis, we divided patients into three groups: patients assuming
Sev (n = 29), patients assuming lanthanum (n= 16) and patients not
assuming any phosphate binder (no binder) (n = 12) . Importantly,
at our institution, the choice of the drug (Sev or lanthanum) to be
used in hyperphosphatemic patients is left entirely free to the
medical doctor taking care of these patients. Therefore no explicit
bias was introduced in the composition of the Sev and lanthanum
subgroups by ‘‘a priori’’ selection criteria. The dose of either
lanthanum or Sev was adjusted, as usual, to the target PO4 and,
therefore, different doses were used in different patients.
Chemistries
The following blood chemistries were determined by standard
laboratory procedures in the venous blood samples collected from
our patients: urea nitrogen, creatinine, bicarbonate, Na+, K+, PO4,
Ca2+, intact PTH (iPTH), albumin, total cholesterol, and high
density lipoprotein (HDL)-cholesterol, triglycerides, hemoglobin,
glycosylated hemoglobin (HbA1c) and high sensibility C-reactive
protein (hs-CRP). Urea nitrogen, creatinine, Na+, K+, PO4, and
proteins were also measured in samples from 24 h urine specimens
and from peritoneal effluent.
In all the recruited patients, residual glomerular filtration rate
(rGFR), total, renal and peritoneal creatinine clearance, normal-
ized protein catabolic rate (nPCR) and total, renal and peritoneal
weekly dialysis dose (Kt/V) were evaluated at the time of the
study.
p-Cresol assay
p-Cresol plasma concentrations were determined by a slightly
modified version of the HPLC method proposed by De Smet et al.
[22]. This method involves a preliminary acidification of the
plasma sample to release bound p-cresol conjugates from plasma
proteins, so that total (bound + free) p-cresol-conjugates become
available for further HPLC analysis. Plasma acidification also
causes the hydrolysis of both p-cresylsulphate and p-cresylglucur-
onide that are converted in p-cresol. Therefore, what is measured
by this method is mainly p-cresylsulfate [6]. Briefly, the
experimental procedure was performed as follows: plasma samples
(300 ml) were acidified by adding half a volume of 25% w/v
perchloric acid (150 ml) to release p-cresol from plasma proteins.
After 10 s vortexing, 600 ml of ethyl acetate was added to the
sample to extract p-cresol and the resulting mixture was saturated
with 100 mg of NaCl and vortexed for 10 s. The sample was then
centrifuged at 865 g for 5 minutes and the supernatant containing
p-cresol was collected in a new tube and centrifuged again at the
same speed. The clear supernatant obtained after this second
centrifugation was collected and injected on a reversed-phase
Ascentis C18 HPLC column with a Supelguard Ascentis C18,
guard column (both from Supelco, Bellefonte, PA, USA) mounted
on a LC-10AD VP HPLC apparatus (Shimadzu- Corporation,
Kyoto, Japan). p-Cresol was eluted isocratically using acetonitrile/
water 40:60 (v/v) as mobile phase (flow rate 1.0 ml/min) and
measured using a Waters 470 fluorescence detector set at the
excitation wavelength of 275 nm and at the emission wavelength
of 300 nm. Under these conditions the retention time of p-cresol
was 8.660.30 min. Peak identity was confirmed by mass
spectrometry analysis using an API 3000 triple quadrupole mass
spectrometer (Applied Biosystems, Canada) equipped with a
Turbo-Ion Spray source. The HPLC system was calibrated by
using standard solutions prepared by diluting p-cresol in methanol
to the final concentrations of 13.5, 27.0, 54.0, 108.0, and
215.0 ng/ml. Under our experimental conditions, the limits of
quantification (signal/noise ratio = 10) and of detection (signal/
noise ratio = 3) of the technique, as evaluated on synthetic
standards, were 0.060 and 0.017 ng/ml, respectively.
All chemicals and reagents were of either analytical or HPLC
grade and were purchased from Delchimica (Naples, Italy). p-
Cresol standard (minimum purity 99%) was from Sigma-Aldrich
(Milan, Italy).
Statistical analysis
Data were analyzed using SPSS 12.0 (SPSS Inc, Chicago, IL)
and Stata12 (Stata corp, College Station, Texas ) setting the
threshold for statistical significance at p values ,0.05. The
Shapiro-Wilk test was performed to assess whether the different
sets of clinical and biochemical data were normally distributed or
not. Normally distributed data are presented as means 6 standard
deviation (SD) whereas skewed data are reported as median with
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interquartile range (IQR). Statistical comparisons among the three
experimental groups (no binder, lanthanum and Sev) were carried
out using univariate ANOVA followed by the Bonferroni post-hoc
test for normally distributed variables and Kruskal-Wallis test
followed by Dunn’s post-hoc test for skewed data. Categorical
variables were expressed as percent and analyzed by x2 test.
Multiple linear regression analysis was performed to identify
factors that were independently correlated with plasma p-cresol
concentrations. Specifically, a general linear model (GLM) was
built using a stepwise method and setting p-cresol plasma
concentration as the dependent variable and the following as
independent variables: total Kt/V, total clearance, rGFR, urine
volume, presence or absence of diabetes, serum albumin, serum
phosphate and serum iPTH. The values of p-cresol concentrations
were ln-transformed before inclusion into the model because they
were not-normally distributed. Post-hoc statistical power analysis
for linear regression models was performed according to the
method of Cohen [23]. Pearson correlation was used to analyze
the correlation between ln plasma p-cresol concentration and dose
of Sev.
Results
57 ESRD patients receiving PD and attending the Division of
Nephrology of the Federico II University of Naples as outpatients
were recruited for the study. Fifteen of them were women (26%)
and the remaining 42 men (74%). At the time of study, patients
had a mean age of 59.7614.5 years. Forty-one patients were on
continuous ambulatory peritoneal dialysis and 16 on automated
peritoneal dialysis. Based on whether they assumed or not
phosphate binders and on which binder they assumed, the
patients were stratified in three groups: no binder (n = 12),
lanthanum (n= 16) and Sev (n = 29). 20 patients (Sev =10,
Lanthanum =5, No binder = 5) were treated with calcitriol
(0.25 mg every other day–0.5 mg/day) and 23 (Sev =13, Lantha-
num =5, No binder = 5) with paricalcitol (1 mg every other day–
1 mg/day). Because the therapy with hypophosphatemic drugs was
individually tailored to achieve target plasma PO4 concentrations,
Sev and lanthanum were administered at different dosages in
different subjects (dosage ranges: 1600–14400 and 750–3000 mg/
die for Sev and lanthanum, respectively). There was no significant
difference among the different groups neither in mean age at the
time of the study, nor in mean body weight, or relative percentage
of the two sexes. Also peritoneal dialysis vintage (i.e. the length of
time on dialysis in months) was similar in the three groups. Its
mean in the whole patient population was 25.4622.1 months and
in all cases it was longer than six months. Six patients in each of
the three patient groups were diabetic. No difference was observed
among Sev , lanthanum and no binder groups in mean percentage
of HbA1c . It was ,7% in both groups suggesting that a good
glycemic control was obtained both in all patient groups [24–25].
All data we reported so far suggest that Sev-treated, lanthanum-
treated and no binder patients are very similar in their
demographic, clinical and laboratory profile (Table 1 and
Table 2). Nevertheless, significant differences emerged when we
compared total p-cresol plasma concentrations. Plasma levels of
this uremic toxin were significantly lower in Sev than lanthanum or
no-binder groups [median and IQR: 3.3 (1.4–6.9) vs 7.9 (4.1–9.8)
and 9.2 (4.3–15.9) in Sev, lanthanum and no binder groups,
respectively; H= 9.6, p,0.008] (Fig. 1 and Table 2). In addition,
in Sev-treated patients plasma p-cresol concentration was linearly
related to the dose of the PO4 binder assumed by the patient being
higher Sev doses associated to lower concentrations of this uremic
toxin (r =20.319; P= 0.025) (Fig. 2). Another relevant difference
was observed in hs-CRP concentrations that were significantly
lower in Sev than in lanthanum or no-binder groups (median and
IQR: 3.8 (1.2–6.6) vs 6.3 (2.6–10.0) and 5.9 (3.4–8.4) in Sev,
lanthanum and no binder groups, respectively; H=10.2,
p,0.006) (Table 2). No significant difference was observed neither
in total creatinine clearance, weekly Kt/V, rGFR and urine
volume suggesting that residual renal function and dialysis
efficiency were similar in these three groups (Table 1). Moreover,
also serum albumin concentrations were not significantly different
among the three groups suggesting that the differences in the
plasma concentration of p-cresol, a uremic toxin that circulates
largely bound to serum albumin, could not be explained by a
lower protein-bound fraction (Table 2). Considering that Sev
therapy was started because of concurrent hyperphosphatemia
and that the main pharmacological effect of Sev is to lower PO4, we
compared PO4 circulating levels in the three groups (Table 2). No
difference among groups was found (Table 2) suggesting that the
treatment with the PO4 binder was effective in normalizing PO4
profile.
To identify the factors associated to p-cresol plasma concentra-
tions we performed a stepwise multiple regression analysis. As
shown in Table 3, the only variable significantly associated to
plasma p-cresol was whether the patient assumed or not Sev
(R2 = 0.19; p = 0.001 with a statistical power of 0.90). On the
contrary, we did not observe any significant association between
plasma concentrations of this uremic toxin and either urine
volume, rGFR, total Kt/V, total clearance, nPCR, presence or
absence of diabetes, serum albumin, serum phosphate and serum
iPTH concentrations.
Discussion
The main finding of the present study is that in PD patients the
concomitant use of Sev for hyperphosphatemia is associated with
lower plasma p-cresol concentrations. This was suggested by the
significantly lower plasma p-cresol concentrations in patients
assuming Sev as compared with those assuming no binder or
lanthanum and was confirmed by multiple linear regression
analysis.
How could the association between Sev use and lower plasma p-
cresol concentrations be explained? Because of its experimental
design our study does not allow to establish any causal relationship
Figure 1. Box and whiskers plot of serum p-cresol levels in
patients assuming Sev, lanthanum or no binder. The bars
represent median, 25th and 75th percentile of plasma p-cresol. *
p,0.05 vs no binder at Dunn’s post-hoc test.
doi:10.1371/journal.pone.0073558.g001
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between the variables that were examined. However, some
working hypotheses can be considered. Reasonable hypotheses
are that in our series patients assuming Sev could have lower
protein intake, a better renal function or lower serum albumin
concentrations. Indeed, protein intake, is a limiting factor for the
production by gut resident bacteria of p-cresol [26], that circulates
in plasma bound to serum albumin and is mainly removed from
the blood by the kidney [27]. However, we can reasonably exclude
all these hypotheses because we did not observe any statistically
significant difference among the different groups in the aforemen-
tioned variables. Moreover, neither nPCR or serum albumin or
related parameters of renal function such as urine volume or
rGFR predicted plasma p-cresol concentrations in our GLM.
Similarly, although previous studies showed that diabetes could
per se cause an increase in plasma p-cresol level [28–29], the
prevalence of diabetic patients was not significantly different in our
groups of patients and diabetes did not predict p-cresol
concentrations in our GLM. In our opinion, the more reasonable
hypothesis to explain our findings is, instead, that Sev could
somehow directly lower p-cresol plasma concentrations. This
possibility is supported by the observation that in the Sev group,
plasma p-cresol concentrations were inversely related to the daily
dose of the drug assumed by each patient, suggesting that the effect
could be dose-related. However, the mechanism by which Sev
could lower p-cresol concentration remains unclear. The main
pharmacological effect of Sev is its ability to bind PO4 ions in the
gut, therefore preventing their absorption and, ultimately,
lowering their concentrations in the plasma [18]. However, the
following considerations suggest that it is unlikely that the Sev
affects p-cresol plasma concentrations by lowering serum PO4.
First, a group of our patients assumed another PO4 lowering drug,
lanthanum, but its p-cresol plasma concentrations were similar to
those found in the group of subjects not assuming PO4 binders and
significantly higher than in the group of subjects receiving Sev.
Second, mean serum phosphate and calcium concentrations were
similar in the different groups of patients and in all cases they were
in the ranges recommended by the KDIGO guidelines [30].
Similarly, iPTH levels were in the normal range both in patients
treated with Sev or lanthanum and in those not assuming PO4
binders although the values measured in the latter two groups
were slightly but not significantly higher. All these considerations
seem to exclude that Sev could affect p-cresol levels by its main
action on PO4 intestinal absorption.
A mechanism that could instead explain our findings is the
binding of p-cresol to Sev in the gut. This appears an intriguing
possibility considering that it has been shown that Sev has the
ability to sequester several uremic toxins in the intestinal lumen
Figure 2. Scatter plot of serum p-cresol concentrations as a
function of Sev daily dosage. The white circles correspond to
patients of the no-binder group, the gray circles to those assuming
lanthanum and the black circles to subjects assuming Sev.
doi:10.1371/journal.pone.0073558.g002
Table 1. Demographic data and dialysis and clinical parameters of sevelamer,lanthanum and no-binder patient groups.
All Sevelamer Lanthanum No binder p
Patients (n.) 57 29 16 12
Male Gender (%) 73.7 72.4 81,2 66,7 0.591
Age (years) 59.7614.4 60.3616.1 56.8614.4 63.867.6 0.533
Diabetes (%) 33 28 31 50 0.375
Body Weight (kg) 76.3614.1 76.8612.7 77.2615.5 73.1617.5 0.778
Dialysis vintage (months) 20 (6–32) 12 (6–32) 27 (22–33) 12 (6–26) 0.082
Total clearance (L/week/1.73 m2) 64.8 (54.8–84.9) 71.3 (58.7–84.4) 61.3 (54.8–69.1) 70.0(49.8–90.4) 0.265
Renal clearance (L/week/1.73 m2) 30.0 (4.9–44.5) 32.7 (0.0–49.2) 22.6 (3.1–40.7) 32.5 (11.1–41.9) 0.580
Dialysis clearance (L/week/1.73 m2) 37.0 (30.0–48.4) 36.0 (29.4–52.0) 39.1 (30.0–47.9) 40.6 (32.5–46.7) 0.745
Total weekly Kt/V 1.86 (1.68–2.22) 1.9 (1.69–2.24) 1.73 (1.41–1.93) 2.11 (1.75–2.44) 0.119
Renal weekly Kt/V 0.67 (0.14–1.09) 0.67 (0.00–1.18) 0.57 (0.07–1.08) 0.87 (0.34–1.39) 0.682
Dialysis weekly Kt/V 1.14 (0.81–1.65) 1.12 (0.79–1.72) 1.12 (0.78–1.61) 1.37 (1.02–1.60) 0.808
Residual GFR (ml/min per 1.73 m2) 2.8 (0.4–4.0) 2.8 (0.0–5.1) 2.5 (0.3–3.8) 2.7 (0.5–5.4) 0.737
nPCR (g/kg/day) 0.9760.2 0.9560.2 1.0160.2 0.9860.2 0.684
Urine volume (ml/day) 1200 (650–1850) 1200 (600–1800) 1100 (625–1800) 1350 (619–2470) 0.589
The data shown in the table are expressed as mean 6SD in the case of normally distributed variables or as median (IQR) in the case of skewed data, respectively.
Categorical data are reported as percent values. The last column on the right reports the p values of ANOVA or Kruskal-Wallis test in the case of normally distributed and
skewed data, repectively.
doi:10.1371/journal.pone.0073558.t001
Plasma p-Cresol Lowering Effect of Sevelamer
PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e73558
and, therefore, to prevent their absorption and lower their
circulating concentrations [31–33]. Importantly, this effect has
not been observed with other PO4 binders like lanthanum and,
therefore, it does not seem to be a general characteristic of PO4
binders but a specific property of Sev. However, while there is a
strong evidence of a direct binding of indoxyl-sulphate and urate
to Sev [31–32], the hypothesis that also p-cresol could bind to this
drug has been controversial so far. The binding of this toxin to Sev
has been, indeed, demonstrated in vitro [21], whereas no effect
was observed in a mouse model of CKD [33]. In the only study
performed in human patients [21], Sev was found ineffective in
lowering the plasma concentration of p-cresol in a series of 57
hemodialysis patients. The reason of the differences between these
results and ours are unclear but they could be related to the
different dialysis procedure that was used. Recent evidence
suggests, indeed, that the underperfusion that can take place
during extracorporeal hemodialysis could alter the permeability of
the intestinal barrier favoring the passage of intestinal bacterial
products (Intestinal-Renal Syndrome) [34]. Supporting this
hypothesis, McIntyre et al. recently reported [35] that measurable
levels of endotoxins coming from intestinal bacteria can be
detected in the plasma of hemodialysis patients and, importantly,
that they increase at the time of dialysis. These important results
have been interpreted assuming that dialysis-induced hemody-
namic stress could damage the intestinal mucosa finally leading to
an increase of its permeability to endotoxins [35]. Although a
formal demonstration of this hypothesis by quantitative measure-
ment of intestinal blood flow is still lacking [34], it is tempting to
speculate that Sev could be less effective in preventing p-cresol
absorption in hemodialysis patients because this dialysis procedure
increases the permeability of the intestinal mucosa to the point that
too much p-cresol can escape from Sev and enter the blood.
The present cross-sectional observational study suggests that Sev
could be an effective therapeutic strategy to lower p-cresol
concentrations in PD patients. If confirmed in larger randomized
double blinded clinical trials, this observation could have
important implications for planning the best pharmacological
treatment in PD patients. The concept that lowering p-cresol
concentrations is a priority in CKD patients strongly emerged,
indeed, during the last years because of compelling experimental
evidence showing that this uremic toxin negatively influences the
prognosis of this disease by significantly increasing the cardiovas-
cular risk [34,36]. Unfortunately, no pharmacological treatment
effective in lowering p-cresol is available with the only exception of
AST-120, a non-absorbable carbon adsorbent approved in Japan
that adsorbs both indoxyl-sulphate and p-cresol in the gut [37–38].
Sev could be a good therapeutic choice to lower plasma p-cresol
also considering that, besides lowering p-cresol, it could also
favorably impact on other cardiovascular risk factors in PD
patients. To be specific, Sev is known to decrease serum C-reactive
protein [31,39–45], a well known predictor of cardiovascular risk
[46], and this was also observed in our PD patient series. This
effect has been attributed to a lower absorption of intestinal
endotoxins that causes a decrease in systemic endothelial damage
and its related inflammatory response [47–49]. Moreover, it has
been reported that Sev decreases HbA1C and LDL and increases
HDL and plasma concentrations [39–41,43,50–51]. Consistent
with the ability of Sev to favorably affect cardiovascular risk
factors, a significant decrease in all case and cardiovascular
mortality has been recently reported in a cohort of hemodialysis
patients as compared with patients with a similar impairment in
renal function assuming calcium carbonate or no PO4 binder [52].
The main limitation of this study is in its observational design.
Even though we carefully looked at the homogeneity of the groups
and, indeed, no significant difference was observed between them
Table 2. Biochemical parameters of sevelamer, lanthanum and no-binder patient groups.
All Sevelamer Lanthanum No binder p
Plasma p-cresol (mg/l) 5.3 (2.8–10.1) 3.3 (1.4–6.9) 7.9 (4.1–9.8)* 9.2 (4.3–15.9)* 0.008
Serum hs–CRP (mg/l) 5.8 (2.6–6.6) 3.8 (1.2–6.6) 6.3 (2.6–10.0)* 5.9 (3.4–8.4)* 0.006
Serum phosphate (mg/dl) 4.761.0 4.561.0 5.161.0 4.460.7 0.107
Serum calcium (mg/dl) 9.160.7 9.260.6 9.160.9 8.960.6 0.471
iPTH (pg/ml) 196 (106–310) 152 (78–256) 273 (141–334) 251 (177–481) 0.039
Albumin (g/dL) 3.860.4 3.760.4 3.960.5 3.860.4 0.568
Total cholesterol (mg/dL) 164654 151641 180679 180627 0.170
HDL cholesterol (mg/dL) 45616 45613 49621 39611 0.332
Triglycerides (mg/dL) 126 (106–151) 118 (102–151) 125 (111–142) 174 (133–191) 0.177
Hemoglobin (g/dl) 11.461.0 11.261.1 11.460.9 11.861.0 0.328
HbA1c (%) 6.061.2 5.960.9 6.261.6 6.161.1 0.750
As in Table 1, the data shown are expressed as mean 6SD in the case of normally distributed variables or as median (IQR) in the case of skewed data, respectively. The
last column on the right reports the p values of ANOVA or Kruskal-Wallis test in the case of normally distributed and skewed data, respectively. The asterisks indicate a
statistically significant difference at the level of p,0.05 versus Sev group as calculated by Dunn’s post hoc test.
doi:10.1371/journal.pone.0073558.t002
Table 3. Stepwise multiple regression analysis of ln p-cresol
plasma concentrations in peritoneal dialysis patients.
Parameter b-coefficient Standard Error p
Sevelamer Use 20.90 0,405 0.001
Intercept 2.95 0.255 ,0.0001
Sev use was the only variable left in the model because significant at the 0.10
level. The following variables of the original model were excluded because they
did not meet the 0.10 significance level in the stepwise procedure: total
clearance (b=0.04, p = 0.77), rGFR (b=20.07; p = 0.57), urine volume (b=0.02;
p = 0.88), total Kt/V (b=20.06; p = 0.65), presence or absence of diabetes
(b=20.07; p = 0.55), nPCR (b= 0.01; p = 0.95), serum albumin (b= 0.003;
p = 0.98), serum phosphate (b=20.03; p =20.82) and serum iPTH (b=20.11;
p = 0.40).
doi:10.1371/journal.pone.0073558.t003
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in main demographic, clinical or laboratory characteristics, further
double-blinded randomized studies will be mandatory to confirm
our findings.
In conclusion, we reported evidence that Sev could lower p-
cresol levels in PD patients. Considering that Sev also decreased hs-
CRP level, our results suggest that this drug could have an
indication in CKD patients independent from its hypophospha-
temic effect and related to its ability to reduce the high
cardiovascular risk of these subjects by multiple mechanisms also
including a decrease in p-cresol plasma levels.
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